SPECIFIC PATHOGEN FREE MACAQUE BREEDING & RESEARCH PROGRAM

使用兴奋剂治疗注意力缺陷 多动症，这是诊断在2 - 6%的儿童在北 自1990年以来几乎增加了两倍， 源于对这种疾病的更广泛的认识，以及 扩大知识，这种兴奋剂药物仍然是 多年来一直有效，直到成年，没有已知的生产 不良副作用的机制尚未达成共识， 常用的抗多动症药物，安非他明和 哌醋甲酯两种药物都能促进精神活动， 儿童和成人，但都提高细胞外多巴胺水平， 巧合的是，多巴胺的升高增强了运动活动， 形成了帕金森病药物治疗的基础。 悖论是本研究的重点。 是为了研究一个新的假设，即正常的搏动 多巴胺的浓度范围很广， 受体可用性和贩运模式与 神经递质的持续和高供应，这可能导致 为了进行这项研究，我们 克隆猴子的D1和D2多巴胺受体， 这一假设与受体表达在体外和体内， 成像出版物Seeman P和Madras BK 药物哌醋甲酯和安非他明Mol Psychiatry 3 386-396， 1998

The use of stimulant medications for attention deficit hyperactivity, which is diagnosed in 2 - 6% of children in North America, has almost tripled since 1990 The increased usage presumably stems from wider recognition of this disorder, as well as the expanding knowledge that such stimulant medication continues to be effective over years, well into adulthood, without known production of adverse side effects There is yet no consensus on the mechanisms of the commonly used anti-hyperactivity medications, amphetamine and methylphenidate Both drugs promote psychomotor slowing of hyperactive children and adults, yet both raise extracellular dopamine levels Paradoxically, elevation of dopamine enhances motor activity, and forms the basis of medications for Parkinson's disease This apparent paradox is the focus of the pilot study The objective of the research is to investigate a novel hypothesis, that a the normal pulsatile supply of dopamine, with a broad range of c oncen trations, results in a different pattern of receptor availability and trafficking than a constant and high supply of the neurotransmitter, which may result with anti-hyperactivity medications To pursue this research, we are cloning the monkey D1 and D2 dopamine receptors and will investigate this hypothesis with the receptor expressed in vitro and in vivo with imaging PUBLICATION Seeman P and Madras BK Anti-hyperactivity medication methylphenidate and amphetamine Mol Psychiatry 3 386-396, 1998